News
ACAD
20.04
+1.37%
0.27
ACADIA PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 10h ago
Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'
Seeking Alpha · 1d ago
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?
Barchart · 1d ago
Press Release: Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Dow Jones · 2d ago
ACADIA Pharmaceuticals Price Target Announced at $22.00/Share by Deutsche Bank
Dow Jones · 3d ago
Acadia Pharmaceuticals initiated with a Hold at Deutsche Bank
TipRanks · 3d ago
U.S. RESEARCH ROUNDUP-Applovin, Incyte, Onsemi
Reuters · 3d ago
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
NASDAQ · 4d ago
Weekly Report: what happened at ACAD last week (0203-0207)?
Weekly Report · 4d ago
TD Cowen Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)
TipRanks · 02/07 13:15
Guru Fundamental Report for ACAD
NASDAQ · 02/06 21:00
Morgan Stanley Remains a Hold on ACADIA Pharmaceuticals (ACAD)
TipRanks · 02/06 13:15
Weekly Report: what happened at ACAD last week (0127-0131)?
Weekly Report · 02/03 09:28
Optimistic Buy Rating for ACADIA Pharmaceuticals Driven by Patient Growth and Strategic Marketing
TipRanks · 01/31 13:25
Weekly Report: what happened at ACAD last week (0120-0124)?
Weekly Report · 01/27 09:29
TD Cowen Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
TipRanks · 01/21 15:15
Pacira appoints Teehan as CCO, Corbett as CBO
TipRanks · 01/21 13:21
Weekly Report: what happened at ACAD last week (0113-0117)?
Weekly Report · 01/20 09:27
ACADIA PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 01/17 21:05
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)
Barchart · 01/16 09:32
More
Webull provides a variety of real-time ACAD stock news. You can receive the latest news about Acadia Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.